Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024

ZEVRA THERAPEUTICS, INC.

FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.
Meeting scheduled for August 2, 2024; background materials released two business days prior.
PDUFA action date for arimoclomol is September 21, 2024.
Arimoclomol is an orally delivered, first-in-class treatment for NPC, a rare genetic disease.
Zevra CEO highlights opportunity for NPC community to share treatment needs with the advisory committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.